Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Zyrtec Could Be A Star If Ads Show Efficacy Over Claritin – UCSF’s Soller

This article was originally published in The Tan Sheet

Executive Summary

A successful Rx-to-OTC switch of Pfizer's non-sedating antihistamine Zyrtec will depend largely on the marketer's ability to communicate the drug's advantages over Claritin through consumer marketing efforts, according to Bill Soller, PhD, executive director, Center for Consumer Self Care, UCSF School of Pharmacy

You may also be interested in...



Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J

Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings

Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J

Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings

Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J

Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings

Related Content

Topics

UsernamePublicRestriction

Register

PS099523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel